Featured Research

from universities, journals, and other organizations

Conquering a severe complication of celiac disease

Date:
May 3, 2010
Source:
Journal of Clinical Investigation
Summary:
One severe complication of celiac disease is enteropathy-associated T cell lymphoma, an invasive lymphoma with poor prognosis. New research has identified the anti-death signals transmitted to immune cells in the wall of the small intestine by the soluble factor IL-15 that contribute to the development of enteropathy-associated T cell lymphoma, providing potential new targets for treating type II refractory celiac disease -- an intermediary clinical state between celiac disease and enteropathy-associated T cell lymphoma.

One severe complication of celiac disease is enteropathy-associated T cell lymphoma, a high-grade invasive lymphoma with a very poor prognosis. Previous research has suggested that chronic exposure of immune cells in the walls of the small intestine, which are known as intraepithelial lymphocytes, to potent anti-death signals initiated by the soluble factor IL-15 contributes to the development of enteropathy-associated T cell lymphoma.

A team of researchers, at INSERM U989, Universitι Renι Descartes, France, has now identified the survival signals delivered by IL-15 to freshly isolated human intraepithelial lymphocytes and to intraepithelial lymphocyte cell lines derived from patients with type II refractory celiac disease -- a clinical state considered an intermediary step between celiac disease and enteropathy-associated T cell lymphoma. Importantly, treatment with an antibody directed at IL-15 caused intraepithelial lymphocytes to die and wiped out their accumulation in mice overexpressing human IL-15 in the lining of their gut.

The team, led by Nadine Cerf-Bensussan and Bertrand Meresse, therefore suggests that IL-15 and its downstream survival signals might provide new targets for the treatment of type II refractory celiac disease.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Malamut et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI41344

Cite This Page:

Journal of Clinical Investigation. "Conquering a severe complication of celiac disease." ScienceDaily. ScienceDaily, 3 May 2010. <www.sciencedaily.com/releases/2010/05/100503174020.htm>.
Journal of Clinical Investigation. (2010, May 3). Conquering a severe complication of celiac disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/05/100503174020.htm
Journal of Clinical Investigation. "Conquering a severe complication of celiac disease." ScienceDaily. www.sciencedaily.com/releases/2010/05/100503174020.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins